GlassScriptPhysician profile
John Bates Hipps
NPI 1174588222
$314.67
in general payments reported to CMS, 2019-2025
9 companies · $89.29 in 2025
The $89.29 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $58.18 · 2021: $90.42 · 2022: $36.96 · 2023: $15.30 · 2024: $24.52 · 2025: $89.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $102.68 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.47 | 2025 | |
| Vifor Pharma, INC. | $48.52 | 2021-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $24.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2025 | Jardiance |
| Philips North America LLC | $19.55 | 2022 | |
| Merck Sharp & Dohme LLC | $17.41 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.54 | 2021 | |
| Novo Nordisk INC | $15.30 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hipps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.